<img alt="" height="1" width="1" />
Medivation, Pfizer drug fails Alzheimer&#39;s study
Reuters
NEW YORK, March 3 (Reuters) - Medivation Inc (MDVN.O) and Pfizer (PFE.N) said on Wednesday their experimental drug, Dimebon, failed to meet the main goals in a highly anticipated late-stage clinical trial for Alzheimer&#39;s disease. ...
Pfizer Alzheimer&#39;s disease drug fails in studyThe Associated Press
Pfizer, Medivation&#39;s Dimebon Fails to Help Alzheimer&#39;s PatientsBusinessWeek
BREAKING NEWS: Medivation&#39;s Dimebon fails Phase III for Alzheimer&#39;sFierceBiotech
TheStreet.com -MarketWatch -Bizjournals.com
all 26 news articles &raquo;


More...